PIK3CA hotspot mutations (~40% of HR+/HER2- metastatic breast cancer): alpelisib + fulves...
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
| ID | BMA-PIK3CA-E545K-BREAST |
|---|---|
| Type | Pertinence thérapeutique |
| État | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Maladies | DIS-BREAST |
| Sources | SRC-CIVIC SRC-ESMO-BREAST-METASTATIC-2024 SRC-NCCN-BREAST-2025 |
Faits relatifs à l ' action en justice
| Biomarqueur | BIO-PIK3CA-MUTATION |
|---|---|
| Variante | E545K |
| Maladie | DIS-BREAST |
| Niveau ESCAT | IA |
| Combinaisons recommandées | alpelisib + fulvestrant, inavolisib + palbociclib + fulvestrant, capivasertib + fulvestrant |
| Résumé des faits | PIK3CA hotspot mutations (~40% of HR+/HER2- metastatic breast cancer): alpelisib + fulvestrant improves PFS vs fulvestrant alone (SOLAR-1, André et al. NEJM 2019) in PIK3CA-mut after AI failure. Inavolisib + palbociclib + fulvestrant (INAVO120, Turner et al. NEJM 2024) improves PFS in 1L PIK3CA-mut HR+/HER2- with ET-resistance — FDA-approved 2024. Capivasertib + fulvestrant (CAPItello-291, Turner et al. NEJM 2023) also active in PIK3CA-mut. |
Notes
ESCAT IA. OncoKB Level 1. E545K is a helical-domain (exon 9) hotspot. Companion diagnostic: therascreen PIK3CA + Guardant360 CDx + FoundationOne Liquid CDx. Hyperglycemia is class-effect AE for alpelisib.
Utilisé par
No reverse references found in the YAML corpus.